Search results
Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.
Quartz· 7 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar...
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Zacks via Yahoo Finance· 1 day agoBristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails...
Drugmakers in Medicare Price Talks Spent Less on R&D Than on Shareholders, Marketing, Overhead:...
The Fiscal Times via Yahoo Finance· 5 days agoEight drug companies that make the 10 medications whose prices are currently being negotiated by...
FogPharma, Artbio join forces to design a different radiopharma drug
BioPharma Dive via Yahoo Finance· 13 hours agoThe biotechs aim to marry FogPharma’s polypeptide science with Artbio’s lead-based...
India's Alembic Pharma posts higher Q4 profit on strong N.America sales
Reuters· 6 days agoIndian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday,...
A Look at Pharma ETFs Post Q1 Earnings - Bristol-Myers Squibb (NYSE:BMY), First Trust Nasdaq...
Benzinga· 5 days agoThe first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of...
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
Pharmaceutical Technology via Yahoo Finance· 1 day agoZai Lab has announced that its New Drug Application (NDA) for Augtyro (repotrectinib) has been...
Cytokinetics shows hand in high stakes rivalry with BMS' Camzyos
FierceBiotech· 1 day agoCytokinetics has set out to prove that aficamten is a threat to Bristol Myers Squibb’s $13.1 billion...
Health Care Roundup: Market Talk
The Wall Street Journal· 1 day agoNEWSPLUS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1506 ET...
Health Care Flat as Traders Digest Earnings Data - Health Care Roundup
Market Watch· 1 day agoHealth-care companies were more or less flat as traders digested a mixed earnings season. While the health-care industry group was among the weakest on the S&P 500 for first-quarter earnings ...